Cost-effectiveness of different strategies with biologics for the treatment of moderate to severe Crohn’s disease in China
Adding biologic treatment lines provides greater health benefits for patients with moderate to severe CD. Among the various sequential strategies, the treatment sequence combining ADA and UST is more likely to be the optimal cost-effective option in China.
Authors
- Fangxu Wang (ORCID: https://orcid.org/0000-0003-4553-4121)
- Chang Liu
- Yao Wu
- Shuang Sun
- Li-Bo Tao
- Yi Yan
Institutions
- Peking University (CN)
Publication Details
- Journal
- World Journal of Gastroenterology
- Published
- 2026-02-10
- DOI
- https://doi.org/10.3748/wjg.v32.i8.115291
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00